SCHEMBL30990799

SCHEMBL30990799

Cn1c(=O)n(C2CCC(=O)N(COCC[Si](C)(C)C)C2=O)c2cccc(N3CCC(C4OCCO4)CC3)c21

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30990629 0.88 DGAT1 (0.30) —
SCHEMBL30990664 0.88 — —
SCHEMBL30990736 0.87 DDB1 (0.32) —
SCHEMBL30990713 0.84 HCRTR1 (0.30) —
SCHEMBL30990639 0.84 DGAT1 (0.30) —
SCHEMBL30990663 0.84 DDB1 (0.31) —
SCHEMBL30990585 0.84 — —
SCHEMBL30990651 0.83 OPRM1 (0.35) —
SCHEMBL31731637 0.81 DDB1 (0.33) —
SCHEMBL30990774 0.81 DDB1 (0.33) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070917-A1 CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF DIFFERENTIATED THERAPEUTICS INC (US) 2026-03-12 — — US disclosed
US-20260062426-A1 CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF DIFFERENTIATED THERAPEUTICS INC (US) 2026-03-05 — — US disclosed
EP-4673449-A1 CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF Differentiated Therapeutics Inc (US) 2026-01-07 — — EP disclosed
EP-4665332-A2 CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF Differentiated Therapeutics Inc (US) 2025-12-24 — — EP disclosed
WO-2024182555-A1 CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF DIFFERENTIATED THERAPEUTICS, INC. (US) 2024-09-06 — — WO disclosed
WO-2024173412-A2 CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF DIFFERENTIATED THERAPEUTICS, INC. (US) 2024-08-22 — — WO disclosed
Send feedback